Moloney E, Mashayekhi A, Sharma S, Kontogiannis V, Ansaripour A, Brownlee W
Front Neurol. 2024; 15:1479476.
PMID: 39711787
PMC: 11659144.
DOI: 10.3389/fneur.2024.1479476.
Kalia L, Asis A, Arbour N, Bar-Or A, Bove R, Di Luca D
Nat Rev Neurol. 2024; 20(12):724-737.
PMID: 39375563
DOI: 10.1038/s41582-024-01023-0.
Dias M, Dorr F, Garthof S, Schafer S, Elmers J, Schwed L
Front Hum Neurosci. 2024; 18:1449388.
PMID: 39345945
PMC: 11427396.
DOI: 10.3389/fnhum.2024.1449388.
Demuth S, Ed-Driouch C, Dumas C, Laplaud D, Edan G, Vince N
Eur J Neurol. 2024; 32(1):e16363.
PMID: 38860844
PMC: 11618115.
DOI: 10.1111/ene.16363.
Moccia M, Affinito G, Marrazzo G, Ciarambino T, Di Procolo P, Confalonieri L
Neurol Int. 2024; 16(2):394-405.
PMID: 38668126
PMC: 11054722.
DOI: 10.3390/neurolint16020029.
Cost avoidance from health system specialty pharmacist interventions in patients with multiple sclerosis.
Georgieva D, Markley B, DeClercq J, Choi L, Zuckerman A
J Manag Care Spec Pharm. 2024; 30(4):336-344.
PMID: 38555624
PMC: 10981971.
DOI: 10.18553/jmcp.2024.30.4.336.
Task-oriented exercise effects on walking and corticospinal excitability in multiple sclerosis: protocol for a randomized controlled trial.
Moslemi Z, Toledo-Aldana E, Baldwin B, Donkers S, Eng J, Mondal P
BMC Sports Sci Med Rehabil. 2023; 15(1):175.
PMID: 38129896
PMC: 10734154.
DOI: 10.1186/s13102-023-00790-5.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T
Ther Adv Neurol Disord. 2023; 16:17562864231200627.
PMID: 37954917
PMC: 10638874.
DOI: 10.1177/17562864231200627.
Work Adjustments by Types of Occupations Amongst People with Multiple Sclerosis: A Survey Study.
Machado A, Murley C, Dervish J, Teni F, Friberg E
J Occup Rehabil. 2023; 34(2):461-471.
PMID: 37923959
PMC: 11180149.
DOI: 10.1007/s10926-023-10142-2.
Alterations of Oligodendrocyte and Myelin Energy Metabolism in Multiple Sclerosis.
Lopez-Muguruza E, Matute C
Int J Mol Sci. 2023; 24(16).
PMID: 37629092
PMC: 10454078.
DOI: 10.3390/ijms241612912.
The Diversity of Astrocyte Activation during Multiple Sclerosis: Potential Cellular Targets for Novel Disease Modifying Therapeutics.
Barmpagiannos K, Theotokis P, Petratos S, Pagnin M, Einstein O, Kesidou E
Healthcare (Basel). 2023; 11(11).
PMID: 37297725
PMC: 10253053.
DOI: 10.3390/healthcare11111585.
Determinants of early working impairments in multiple sclerosis.
Moccia M, Fontana L, Palladino R, Falco F, Finiello F, Fedele M
Front Neurol. 2022; 13:1062847.
PMID: 36570442
PMC: 9784221.
DOI: 10.3389/fneur.2022.1062847.
Adipokines in multiple sclerosis patients are related to clinical and radiological measures.
Loonstra F, Falize K, de Ruiter L, Schoonheim M, Strijbis E, Killestein J
J Neurol. 2022; 270(4):2018-2030.
PMID: 36562851
PMC: 10025234.
DOI: 10.1007/s00415-022-11519-8.
Ensemble machine learning identifies genetic loci associated with future worsening of disability in people with multiple sclerosis.
Fuh-Ngwa V, Zhou Y, Melton P, van der Mei I, Charlesworth J, Lin X
Sci Rep. 2022; 12(1):19291.
PMID: 36369345
PMC: 9652373.
DOI: 10.1038/s41598-022-23685-w.
Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies.
Simoens S
Front Neurol. 2022; 13:1015256.
PMID: 36341111
PMC: 9631775.
DOI: 10.3389/fneur.2022.1015256.
Persistence, adherence, healthcare resource utilization and costs for ocrelizumab in the real-world of the Campania Region of Italy.
Moccia M, Affinito G, Berera G, Marrazzo G, Piscitelli R, Carotenuto A
J Neurol. 2022; 269(12):6504-6511.
PMID: 35953597
PMC: 9618479.
DOI: 10.1007/s00415-022-11320-7.
Multiple Sclerosis: Therapeutic Strategies on the Horizon.
Manjunatha R, Habib S, Sangaraju S, Yepez D, Grandes X
Cureus. 2022; 14(5):e24895.
PMID: 35706718
PMC: 9187186.
DOI: 10.7759/cureus.24895.
Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.
Weinstein D, Owens G, Gandhi A
Am Health Drug Benefits. 2022; 15(1):13-20.
PMID: 35586614
PMC: 9038003.
Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting.
Wang Y, Pleasure D, Deng W, Guo F
Adv Sci (Weinh). 2021; 9(5):e2102853.
PMID: 34935305
PMC: 8844485.
DOI: 10.1002/advs.202102853.
Developing a community-engaged wheelchair exercise program for persons with MS: community advisory board formation and feedback.
Silveira S, Froehlich-Grobe K, Motl R
Disabil Rehabil Assist Technol. 2021; 18(8):1385-1392.
PMID: 34892990
PMC: 9215208.
DOI: 10.1080/17483107.2021.2010819.
